Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The Play Is for xB3
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Dec 28, 2022 10:27am
96 Views
Post# 35193435

RE:RE:RE:RE:RE:The Play Is for xB3

RE:RE:RE:RE:RE:The Play Is for xB3Hah!

prophetofthepast says, "Rathjen has done what should have been done a long, long time ago."

Rathjen gave up years ago, first with the Prothena deal, over four years ago. The Chiesi deal cemented her legacy of incompetence. 

Imagine! She sold four LSDs to Chiesi and the rights to more for $3 million and then has the temerity to pump Hunter sysndrome as Bioasis's top program, despite having several potential blockbusters under her care. I suppose they were being safely guarded on the shelf by her, undedr her care, for others to exploit.

She gave up long ago. She doesn't even read financial reports she signs, contracts the company has entered, or presentations that have the possibility of containing disclosures for others more worthy of dosclosure than Bioasis shareholders.

What I wonder is how many surprises she has not discovered that are contained in the many agreements that form this sellout.

My goodness, stick to copy/pasting the party line.

JD

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities